Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2022-01-17 Investor Presentation
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PR - PHARMANUTRA Cetilar USA patent
Investor Presentation Classification · 1% confidence The document is an official communication identified by the header 'Informazione Regolamentata' (Regulated Information) from Euronext Star Milan, dated January 17, 2022. The subject is 'PR - PHARMANUTRA Cetilar USA patent' and the content details the granting of a new patent in the U.S. for the use of Cetylated Fatty Acids (CFA), which is intellectual property news. This type of announcement, concerning patents, intellectual property, or significant corporate developments that are not standard periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or specific IP/Legal categories. Since there is no specific code for 'Patent Grant Announcement' and it is a formal regulatory disclosure, it best fits the 'Regulatory Filings' (RNS) category, which serves as a catch-all for official, non-standard disclosures. It is not an Earnings Release (ER), Interim Report (IR), or a formal Audit Report (AR). Given the nature of the announcement (a specific corporate event disclosure), RNS is the most appropriate general regulatory classification.
2022-01-17 English
CS - PHARMANUTRA Brevetto cetilar USA
Regulatory Filings Classification · 1% confidence The document is an official communication from PHARMANUTRA S.P.A. dated January 17, 2022, identified as 'Informazione Regolamentata n. 20106-5-2022' (Regulated Information). The subject is 'CS - PHARMANUTRA Brevetto cetilar USA' (CS - PHARMANUTRA Cetilar Patent USA). The content details the granting of a new patent in the USA regarding the use of Cetylated Fatty Acids (CFA), the functional principle behind their Cetilar® medical devices. This is a specific announcement regarding intellectual property and product development, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a general regulatory filing (RNS). It is a specific corporate action announcement. Given the options, this type of announcement, which details a significant corporate development (patent grant) often released via regulatory channels, fits best under the general 'Regulatory Filings' (RNS) category as a specific corporate event disclosure, although it is highly specific. However, since it is a direct announcement of a corporate event/development rather than a financial report or management change, and there is no specific code for 'Intellectual Property Announcement', RNS serves as the most appropriate general regulatory disclosure category for non-standard financial reports. The document structure strongly suggests a regulatory news service release (indicated by 'Informazione Regolamentata' and the structure).
2022-01-17 Italian
PR PHARMANUTRA - Corporate events 2022
Report Publication Announcement Classification · 1% confidence The document is a short announcement (4373 characters) from PHARMANUTRA S.P.A. dated January 14, 2022. The subject is the 'PUBLICATION OF THE 2022 CORPORATE EVENTS CALENDAR,' which lists future dates for board meetings and shareholder meetings related to approving financial results (Financial Statements, Interim Management Statements, Half-Yearly Report). Since the document itself is not the financial report (10-K, IR, ER) but rather an announcement about the *publication schedule* of future reports, it fits the definition of a Report Publication Announcement (RPA). This aligns with Rule 2 ('MENU VS MEAL' Rule) where short announcements detailing the release of reports are classified as RPA.
2022-01-14 English
CS PHARMANUTRA - Eventi societari 2022
Report Publication Announcement Classification · 1% confidence The document is a short regulatory announcement (Informazione Regolamentata) from PHARMANUTRA dated January 14, 2022. The subject ('Oggetto') is 'CS PHARMANUTRA - Eventi societari 2022' (Corporate Events 2022). The core content is a table listing future dates for Board of Directors meetings to approve financial results (Annual Report, Quarterly Reports) and the Shareholders' Meeting for approval. Since the document itself is not the financial report (like 10-K or IR) but rather an announcement detailing *when* those reports will be published, it fits the definition of a Report Publication Announcement (RPA). The document is short (4667 chars) and explicitly announces the schedule for future report releases.
2022-01-14 Italian
PR - PHARMANUTRA new agreement in Taiwan
Regulatory Filings Classification · 1% confidence The document is an official communication from PHARMANUTRA S.P.A. dated January 13, 2022, identified by the header 'Informazione Regolamentata n. 20106-2-2022' and the 'Tipologia: REGEM'. The subject is a 'new agreement in Taiwan' regarding product distribution. This type of announcement, detailing a significant business development (a new distribution agreement), does not fit the specific financial reporting categories (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general regulatory announcement concerning business operations. Since it is a formal, market-sensitive announcement that doesn't fit a more specific category like M&A (TAR) or Director's Dealing (DIRS), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory disclosure.
2022-01-13 English
CS - PHARMANUTRA nuovo accordo Taiwan
Regulatory Filings Classification · 1% confidence The document is a press release from PHARMANUTRA S.P.A. dated January 13, 2022. The subject ('Oggetto') is 'CS - PHARMANUTRA nuovo accordo Taiwan' (Press Release - PHARMANUTRA new agreement Taiwan). The content details a new distribution agreement for a product in Taiwan. This type of announcement, which communicates a specific business event (like a new contract or partnership) outside of routine financial reporting periods (like earnings or annual reports), typically falls under general regulatory announcements or press releases. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific management/board change (MANG), nor a transaction in own shares (POS), the most appropriate general category for a significant business update that is not explicitly covered elsewhere is Regulatory Filings (RNS), which serves as a broad category for official company news releases not fitting stricter definitions. The document length is moderate (5124 chars), suggesting it is the full announcement, not just a notification of publication (RPA).
2022-01-13 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.